which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Vigil Neuroscience said the Food and Drug Administration removed a partial clinical hold on its ongoing Phase 1 clinical trial of a treatment for Alzheimer's disease, VG-3927. The clinical-stage ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some ... a third of people living with dementia in the UK don’t get a diagnosis at all.

But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Researchers at UCLA Health have discovered a molecule that shows promise in restoring memory and cognitive function in mice ...

As Gladstone Institutes commemorates World Alzheimer’s Month, Lennart Mucke, MD, discusses what’s next for Alzheimer’s ...

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

But what if there were drugs already on the ... Results suggest that estradiol, an FDA-approved estrogen replacement therapy, could be effective for treating Alzheimer's in the APOE genotype.